PHILADELPHIA, Feb. 15, 2022 (World NEWSWIRE) — Scout Bio, a biotechnology corporation producing therapeutic proteins and a person-time AAV gene therapies for big serious pet well being problems, today announced that it will existing at two conferences in February 2022. They involve:
- Animal Well being, Nutrition and Technological know-how Innovation Europe (In-individual). Scout Bio is a sponsor of the function, and management will host a technical insights session reviewing the company’s platform and pipeline on February 22 at 3:15 p.m. GMT.
- Bank of America Securities Animal Overall health Summit (Virtual). Scout Bio Chief Govt Officer Mark Heffernan, Ph.D., will give a company overview on Thursday, February 25, 2022 at 10:50-11:30 a.m. EST.
About Scout Bio
Scout Bio is a biotechnology firm revolutionizing pet drugs by delivering a pipeline of biological proteins and one-time gene therapies for significant continual pet overall health conditions. Scout Bio’s AAV gene therapies are built to induce lengthy-phrase expression of therapeutic proteins in pet individuals employing AAV vector technologies. Scout Bio has a investigate and improvement collaboration with the University of Pennsylvania’s Gene Treatment Method, a leader in the area of genetic medication study. Scout Bio is a personal firm headquartered in Philadelphia, Pennsylvania. For additional data, see www.scoutbio.co.
For even more facts, you should make contact with:
Fran Gaconnier
Scout Bio
214.417.4142
fran.gaconnier@scoutbio.co